IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq:ELGX) today announced the successful treatment of the first thoracic aortic dissection patient with the Company’s Powerlink® Dissection Stent System (DSS). The Powerlink DSS, a variant of the Powerlink technology without the ePTFE graft cover, is being used as an investigational device in the European Union and is not currently available in the United States.
